Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
BCABBioatla
10assets
Bioatla
- Ozuriftamab vedotinBA3021 / ROR2 / CAB antibody-drug conjugate / OncologyOPSCCPhase 3
- Mecbotamab vedotinBA3011 / AXL / CAB antibody-drug conjugate / OncologySarcoma (soft tissue and bone)Phase 2mKRAS NSCLCPhase 2
- EvalstotugBA3071 / CTLA-4 / CAB antibody / OncologyUnresectable and/or metastatic cutaneous melanomaPhase 2
- BA3182BA3182 / EpCAM x CD3 / Dual CAB T-cell engager / OncologyAdenocarcinomaPhase 1ongoing
- BA3361BA3361 / Nectin-4 / CAB antibody-drug conjugate / OncologySolid tumorsPreclinicalIND-approved
- BA3151BA3151 / B7-H4 / CAB antibody-drug conjugate / OncologyBreast cancerPreclinical
- BA3142BA3142 / B7-H3 x CD3 / Dual CAB T-cell engager / OncologySolid tumorsPreclinicalIND-ready
- BA3311BA3311 / EGFR x CD3 / T-cell engager / OncologySolid tumorsPreclinical
- BA3241BA3241 / Trop2 x CD3 / Dual CAB T-cell engager / OncologySolid tumorsPreclinical
- BA3362BA3362 / Nectin-4 x CD3 / Dual CAB T-cell engager / Oncology